Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
O43921
UPID:
EFNA2_HUMAN
Alternative names:
EPH-related receptor tyrosine kinase ligand 6; HEK7 ligand
Alternative UPACC:
O43921; O76020
Background:
Ephrin-A2, also known as EPH-related receptor tyrosine kinase ligand 6 or HEK7 ligand, is a cell surface GPI-bound ligand for Eph receptors. These receptors are pivotal for neuronal, vascular, and epithelial development, influencing migration, repulsion, and adhesion. Ephrin-A2 engages in bidirectional signaling with Eph receptors on adjacent cells, facilitating both forward and reverse signaling pathways. It is implicated in bone remodeling by potentially regulating osteoclastogenesis and osteoblastogenesis.
Therapeutic significance:
Understanding the role of Ephrin-A2 could open doors to potential therapeutic strategies, particularly in the context of bone diseases and disorders related to neuronal, vascular, and epithelial development.